Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Antiepileptics May Get Class Suicide Warning Though Classwide Risk Was Not Seen

This article was originally published in The Pink Sheet Daily

Executive Summary

Three of the 11 drugs studied did not exhibit a strong suicidality signal, but FDA says the data merit a “black box” warning for all.

You may also be interested in...

FDA Panel Opposes “Boxed” Warning For Increased Suicidality In Anti-Epileptic Drugs

Committee agrees anti-epileptics demonstrate a risk signal for suicidality, but sees potential for more harm than good in adding black box.

Big Pharma Still Hopeful For Next Mega Drugs To Supplement Sales

Drug makers need to continue investing in early-stage research to unveil the next $1 billion-plus drug, panelists at the Argyle conference agree.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts